Tempus AI Unveils Immune Profile Score Test and Presents Research at SITC 2024

Tempus AI Launches Innovative Immune Profile Score Test

Tempus AI, Inc. (NASDAQ: TEM), a leader in AI-driven precision medicine, has announced the clinical launch of its Immune Profile Score (IPS) algorithmic test 3

3

. This groundbreaking multimodal biomarker is designed to serve as a prognostic indicator for adult patients with stage IV and metastatic pan-solid tumors who are candidates for immune checkpoint inhibitor (ICI)-based therapy 3

3

.

Validation Study Reveals Promising Results

The IPS test was validated in a retrospective study involving 1,600 patients with 19 different solid tumor types. The study demonstrated that IPS-High patients were more likely to experience an overall survival benefit while receiving ICI-based therapy compared to IPS-Low patients (HR 0.5) 3

3

. Notably, the IPS test showed prognostic utility independent of other established biomarkers such as tumor mutational burden (TMB), PD-L1 immunohistochemistry (IHC), and microsatellite instability (MSI) status 3

3

.

Advancing Precision Medicine in Oncology

Dr. Ezra Cohen, Chief Medical Officer of Oncology at Tempus, emphasized the significance of this development, stating, "This is Tempus' first time leveraging a multimodal algorithm in the immunotherapy space, and we look forward to providing clinicians the ability to use our IPS test to garner data-driven insights that can inform important treatment decisions" 3

3

.

SITC 2024: Showcasing AI-Driven Research

In addition to the IPS test launch, Tempus announced the acceptance of nine abstracts for presentation at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting, scheduled for November 6-10, 2024, in Houston, Texas 1

1

2

2

. These presentations will highlight Tempus' advancements in harnessing AI and data to drive immunotherapy innovation.

Key Research Highlights

1. Clinical Validation of Multi-Omic Algorithm: A study presenting the development and validation of the Integrated DNA/RNA ICI biomarker, which utilizes Tempus xT (DNA sequencing) and xR (RNA sequencing) to predict patient outcomes to immune checkpoint inhibitors 1

   1

   .

2. Cost-Effectiveness of Molecular Biomarkers: Research modeling the impact of CT imaging patterns on the clinical utility and cost-effectiveness of molecular biomarkers for treatment response monitoring in advanced cancer patients treated with ICIs 1

   1

   .

Implications for Cancer Treatment

Dr. Sandip Patel from UC San Diego Health commented on the potential impact of the IPS test, stating, "IPS scoring can inform tumor-intrinsic sensitivity to immune checkpoint blockade beyond PD-L1 IHC and TMB, and help manage patients on immunotherapy utilizing data already collected as part of DNA and RNA sequencing" 3

3

.

Future Prospects and Challenges

While these developments represent significant progress in precision medicine for cancer treatment, Tempus acknowledges the challenges ahead. The company's forward-looking statements caution about risks related to financial performance, customer retention, regulatory compliance, and competition in the rapidly evolving field of AI in healthcare 2

2

.

As Tempus continues to expand its multimodal data library and AI capabilities, the goal remains clear: to benefit each patient from the collective treatment experiences of others, providing physicians with tools that learn and improve over time 2

2

3

3

.